Go Back to Previous Page »

Lipitor Antitrust Litigation -- Southeast Laborers Health and Welfare Fund v. Pfizer Inc.

Court: United States District Court, District of New Jersey
Case No.: 12-cv-02389
Leadership Position: Interim Co-Lead Class Counsel

Wexler Wallace LLP filed two class actions against Pfizer Inc. and Ranbaxy Pharmaceuticals Inc., among others, seeking damages and equitable relief on behalf of end-payors of Lipitor and/or its generic bioequivalents for violations of antitrust and consumer protection laws.  Plaintiffs allege that defendants fraudulently procured a patent covering Lipitor, and engaged in sham litigation concerning that patent, in order to keep generic versions of the blockbuster drug off of the market.  As a result of these actions, market entry of a generic version of Lipitor was delayed for a number of years, forcing the proposed class to pay more for Lipitor and its generic bioequivalents than they would have in the absence of defendants’ anticompetitive conduct. To view a copy of the complaint, please click here.